Companies / Malaysia
US FTA Lobbying Intensifies
February 2007 | Trade AlertA US business lobby group has restated that drug prices will not rise in Malaysia after the implementation of a US free trade agreement (FTA) and described the pact as a 'win-win' opportunity for both countries. While BMI believes that the enhanced intellectual property environment engendered by the FTA will encourage the evolution of Malaysian research-based drugmakers, particularly biotech start-ups, we are doubtful that medicine prices will not rise. Furthermore, it is BMI's view that negotiations will not be concluded before July, putting the entire FTA in
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Asia Pacific Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Asia Pacific Pharma & Healthcare Insight please click on the trial link below.
